Novo Nordisk said its experimental drug CagriSema demonstrated a weight‑loss advantage over tirzepatide in recent trials.
Further specifics about the study were not immediately available.
Novo Nordisk's CagriSema shows weight loss edge over tirzepatide in trials
Novo Nordisk reported that its experimental drug CagriSema achieved greater weight loss than tirzepatide in clinical trials.
HV
Helena Vásquez · Business Desk · 21 Sept 2026 · 22:27 · 1 Min. Lesezeit
Dieser Artikel wurde mit KI-Unterstützung erstellt und von einer Finances-Review-Redakteurin bearbeitet.
ADVERTISEMENT
HV
Geschrieben von
Helena Vásquez
Business Desk
Helena covers corporate news for listed and private companies across Europe, from strategy shifts to leadership changes, with an eye for what a story signals about the broader market.
Mehr von Helena Vásquez →
